BISPECIFIC ANTI-FLT3/CD3 ANTIBODIES AND METHODS OF USE
Provided herein are bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, such as the antibodies and fragments that specifically bind human FLT3 and human CD3. In some aspects, provided herein are optimized humanized, bispecific anti-FLT3/CD3 antibodies and antigen binding fragm...
Saved in:
Main Authors | , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
23.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided herein are bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, such as the antibodies and fragments that specifically bind human FLT3 and human CD3. In some aspects, provided herein are optimized humanized, bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, optionally, having certain amino acid substitutions that confer advantageous properties (e.g., optimal antigen binding, manufacturability and/or half-life properties). Also provided herein are pharmaceutical compositions comprising such antibodies or fragments. Also provided herein are methods of use of such antibodies and fragments.
L'invention concerne des anticorps bispécifiques anti-FLT3/CD3 et des fragments associés de liaison à l'antigène, tels que les anticorps et les fragments qui se lient spécifiquement à FLT3 humain et à CD3 humain. Selon certains aspects, la présente invention concerne des anticorps humanisés optimisés, des anticorps bispécifiques anti-FLT3/CD3 et des fragments associés de liaison à l'antigène, ayant éventuellement certaines substitutions d'acides aminés qui confèrent des propriétés avantageuses (par exemple, des propriétés optimales en termes de liaison à l'antigène, d'aptitude à la préparation et/ou de demi-vie. L'invention concerne également des compositions pharmaceutiques comprenant de tels anticorps ou fragments. L'invention concerne également des méthodes d'utilisation de ces anticorps et fragments. |
---|---|
Bibliography: | Application Number: WO2022US74981 |